Earnings ·
Regeneron Pharmaceuticals, Inc. expects an acquired in-process research and development charge of approximately $127…
REGNRegeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. expects an acquired in-process research and development charge of approximately $127 million on a pre-tax basis for the second quarter of 2026. This charge, related to collaboration and licensing agreements, is expected to negatively impact GAAP and non-GAAP net income per diluted share by approximately $1.00. Regeneron is a biotechnology company that develops and manufactures biopharmaceutical products.